Exicure received Nasdaq delinquency notice on late filing of Form 10-K
Seeking Alpha News (Mon, 22-Apr 4:20 PM ET)
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
Business Wire (Mon, 22-Apr 4:01 PM ET)
Business Wire (Mon, 5-Feb 4:01 PM ET)
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Exicure trades on the NASDAQ stock market under the symbol XCUR.
As of April 24, 2024, XCUR stock price declined to $0.51 with 18,413 million shares trading.
XCUR has a beta of 2.70, meaning it tends to be more sensitive to market movements. XCUR has a correlation of 0.14 to the broad based SPY ETF.
XCUR has a market cap of $4.45 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, XCUR stock traded as high as $60.87 and as low as $.36.
The top ETF exchange traded funds that XCUR belongs to (by Net Assets): VXF.
XCUR has underperformed the market in the last year with a price return of -45.5% while the SPY ETF gained +24.1%. XCUR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.1% and -14.9%, respectively, while the SPY returned +4.5% and -1.7%, respectively.
XCUR support price is $.51 and resistance is $.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XCUR stock will trade within this expected range on the day.